UK's BIA and MHRA propose patient-centric approach to speeding up development and regulation

The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have published a new report arguing against accusations that the development, approval and patient access process is “broken”.

The report states the bodies’ intentions to learn from the unprecedented response to the Ebola pandemic, in terms of responding to other epidemic threats and in the extent to which these lessons can be learned in other therapeutic areas.

It asserts that the UK has the skills, resources and capabilities needed to speed up drug development and get treatment to patients in a more timely fashion, but that changes can be made.